David S Boyer, MD | UniHealth

Offices

1 location · Retina Vitreous Associates Medical Group · 17 clinicians in this group

Looking this up.

Plan participation

Not verified

We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Boyer’s office at (213) 483-8810 to ask if they take your plan before you enroll.

California Medical Board record

Licence G25107 · Current

Licensed to practise in California · since 1973 · expires 2027-03-31 · Rosalind Franklin University, the Chicago Medical School.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

American Board of Ophthalmology - Ophthalmology

Original Medicare doctor bills

$6,277,649

Medicare paid this office $6,277,649 for 2,440 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Injection, faricimab-svoa, 0.1 mg	176	$1,506,030	None
Injection, pegcetacoplan, intravitreal, 1 mg	111	$1,438,085	None
Injection, aflibercept, 1 mg	223	$1,278,692	None
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	185	$616,792	$176
Injection of drug into eye	675	$347,032	$108

See all 25 services

Sort by

Every Original Medicare service billed

Injection, faricimab-svoa, 0.1 mg	176	$1,506,030	None
Injection, pegcetacoplan, intravitreal, 1 mg	111	$1,438,085	None
Injection, aflibercept, 1 mg	223	$1,278,692	None
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	185	$616,792	$176
Injection of drug into eye	675	$347,032	$108
Established patient complete exam of visual system	1,897	$302,349	$101
Imaging of retina	2,419	$215,593	$34
Injection, aflibercept hd, 1 mg	26	$167,388	None
Injection, ranibizumab, 0.1 mg	38	$83,126	None
Injection, dexamethasone, intravitreal implant, 0.1 mg	27	$66,233	None
Established patient problem focused exam of visual system	541	$64,730	$75
New patient visit (45+ min)	412	$53,312	$129
Exam of retinal blood vessels using a special camera after injection of a dye	186	$27,968	$145
Management using the results of remote vital sign monitoring per calendar month, first 20 minutes	102	$20,594	$43
Destruction of growth of retina using a laser	19	$9,088	$433
Destruction of leaking blood vessels of retina using laser	13	$6,300	$300
2d ultrasound scan of eye tissue and structures	106	$5,877	$37
Injection, bevacizumab, 10 mg	57	$5,519	None
New patient visit (60+ min)	24	$4,248	$177
Extended exam of the back part of the eye with optic nerve drawing	281	$3,678	$11
Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes	43	$3,281	$34
New patient complete exam of visual system	39	$2,123	$54
Photography of the retina	20	$584	$29
Extended exam of the back part of the eye with retinal drawing	22	$424	$19
Office for the evaluation and management of established patient that may not require presence of healthcare professional	13	$251	$19

Procedures year by year

Procedures billed to Original Medicare by year
Procedure	2019	2020	2021	2022	2023	2024
Injection of drug into eye	3,378	3,102	3,189	2,986	3,187	3,224
Destruction of leaking blood vessels of retina using laser	36	27	27	24	24	21
Destruction of growth of retina using a laser	23	12	18	18	–	21
Removal of membrane of retina with removal of internal limiting membrane of retina	32	25	19	–	–	–
Removal of eye fluid (vitreous) between lens and retina	17	–	–	–	–	–
Removal of eye fluid	16	–	–	–	–	–

Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.

Who their Medicare patients are

2,440 Original Medicare patients in 2024. Average age 79 · Under 65 2% · 85 and older 26% · Women 57% · Also on Medicaid 16% · Health risk score 1.47. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.

Conditions among them: High blood pressure 75% · Coronary heart disease 42% · Diabetes 38% · Chronic kidney disease 25% · Depression 20% · Heart failure 19% · Cancer 19% · Atrial fibrillation 19% · COPD 13% · Stroke 10% · Dementia 8%.

The office billed $23,426,487, Medicare allowed $8,005,425 and paid $6,277,649; for 91,510 services of 45 kinds; $5,177,263 of it was for drugs given in the office and $1,100,385 for care.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	2,440	91,510	79	1.47	$23,426,487	$6,277,649
2023	2,417	61,035	79	1.40	$20,453,483	$5,623,730
2022	2,352	29,058	78	1.42	$16,874,938	$4,439,953
2021	2,388	26,975	78	1.43	$17,160,048	$4,608,477
2020	2,186	24,938	78	1.56	$15,853,419	$4,202,914
2019	2,575	28,220	78	1.55	$17,183,147	$4,638,146
2018	2,865	28,670	78	1.55	$17,705,019	$4,919,223
2017	2,873	30,575	78	1.57	$16,979,386	$4,798,013
2016	2,913	30,640	78	1.53	$17,142,700	$4,863,125
2015	2,800	29,239	78	1.50	$16,990,960	$4,916,862
2014	2,768	31,415	77	1.46	$17,546,841	$5,068,106
2013	2,642	30,551	78	1.44	$18,100,424	$5,273,682

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 21 services

Sort by

Original Medicare services billed in 2023

Injection, aflibercept, 1 mg	257	$1,841,977	None
Injection, faricimab-svoa, 0.1 mg	108	$1,008,054	None
Unclassified drugs	107	$670,945	None
Injection of drug into eye	661	$341,931	$107
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	100	$323,658	$216
Injection, pegcetacoplan, intravitreal, 1 mg	85	$321,363	None
Injection, ranibizumab, 0.1 mg	68	$268,598	None
Established patient complete exam of visual system	1,728	$261,463	$102
Imaging of retina	2,397	$222,523	$34
Injection, dexamethasone, intravitreal implant, 0.1 mg	41	$102,627	None
Established patient problem focused exam of visual system	625	$82,806	$75
New patient complete exam of visual system	386	$48,588	$126
Exam of retinal blood vessels using a special camera after injection of a dye	203	$25,245	$121
Injection, bevacizumab, 10 mg	170	$24,929	None
New patient visit (45+ min)	113	$12,353	$109
2d ultrasound scan of eye tissue and structures	125	$7,998	$39
Destruction of leaking blood vessels of retina using laser	16	$6,843	$285
Extended exam of the back part of the eye with optic nerve drawing	277	$3,887	$13
Extended exam involving color vision testing	20	$1,095	$50
Extended exam of the back part of the eye with retinal drawing	46	$971	$21
Office for the evaluation and management of established patient that may not require presence of healthcare professional	18	$489	$20

2022: 22 services

Sort by

Original Medicare services billed in 2022

Injection, aflibercept, 1 mg	283	$2,449,834	None
Injection, ranibizumab, 0.1 mg	113	$606,741	None
Injection of drug into eye	612	$325,154	$109
Established patient problem focused exam of visual system	1,325	$274,967	$73
Imaging of retina	2,328	$207,149	$34
Established patient complete exam of visual system	1,292	$155,323	$98
Injection, faricimab-svoa, 0.1 mg	30	$98,477	None
Injection, dexamethasone, intravitreal implant, 0.1 mg	33	$96,857	None
Unclassified biologics	15	$56,188	None
Injection, bevacizumab, 10 mg	210	$41,657	None
New patient visit (45+ min)	291	$36,284	$125
Exam of retinal blood vessels using a special camera after injection of a dye	139	$16,702	$114
New patient complete exam of visual system	77	$9,502	$123
Destruction of growth of retina using a laser	17	$8,193	$455
2d ultrasound scan of eye tissue and structures	114	$7,574	$41
Destruction of leaking blood vessels of retina using laser	14	$7,259	$302
Injection, triamcinolone acetonide, preservative free, 1 mg	13	$4,899	None
Extended exam of the back part of the eye with optic nerve drawing	122	$1,470	$12
New patient problem focused exam of visual system	17	$1,267	$75
Photography of the retina	17	$543	$30
Extended exam of the back part of the eye with retinal drawing	21	$457	$22
Office for the evaluation and management of established patient that may not require presence of healthcare professional	13	$299	$20

2021: 21 services

Sort by

Original Medicare services billed in 2021

Injection, aflibercept, 1 mg	272	$2,467,228	None
Injection, ranibizumab, 0.1 mg	120	$741,553	None
Injection of drug into eye	636	$346,089	$109
Established patient complete exam of visual system	1,626	$240,166	$103
Established patient problem focused exam of visual system	1,045	$238,404	$74
Imaging of retina	2,252	$210,966	$34
Injection, dexamethasone, intravitreal implant, 0.1 mg	38	$111,279	None
Injection, bevacizumab, 10 mg	257	$59,115	None
New patient visit (45+ min)	290	$38,956	$134
New patient complete exam of visual system	205	$23,427	$114
Removal of membrane of retina with removal of internal limiting membrane of retina	18	$19,197	$1,010
Exam of retinal blood vessels using a special camera after injection of a dye	163	$17,988	$105
Photography of the retina	251	$8,768	$32
Destruction of growth of retina using a laser	17	$8,290	$461
Destruction of leaking blood vessels of retina using laser	17	$8,226	$305
Injection, triamcinolone acetonide, preservative free, 1 mg	19	$5,908	None
Extended exam of the back part of the eye with optic nerve drawing	335	$4,675	$13
2d ultrasound scan of eye tissue and structures	68	$4,090	$43
1d and 2d ultrasound scan of eye tissue and structures	35	$3,049	$64
Extended exam of the back part of the eye with retinal drawing	57	$1,185	$20
New patient problem focused exam of visual system	13	$709	$55

2020: 23 services

Sort by

Original Medicare services billed in 2020

Injection, aflibercept, 1 mg	254	$2,261,135	None
Injection, ranibizumab, 0.1 mg	113	$702,433	None
Injection of drug into eye	642	$297,126	$96
Established patient problem focused exam of visual system	1,009	$193,158	$73
Imaging of retina	2,020	$186,126	$34
Established patient complete exam of visual system	1,431	$182,525	$98
Injection, dexamethasone, intravitreal implant, 0.1 mg	35	$103,310	None
Injection, bevacizumab, 10 mg	221	$43,687	None
New patient complete exam of visual system	259	$31,244	$121
Compounded drug, not otherwise classified	174	$26,301	None
Removal of membrane of retina with removal of internal limiting membrane of retina	24	$25,554	$1,022
Exam of retinal blood vessels using a special camera after injection of a dye	190	$18,531	$95
New patient visit (45+ min)	128	$16,486	$129
Photography of the retina	301	$12,328	$37
Destruction of leaking blood vessels of retina using laser	14	$8,332	$309
Injection, triamcinolone acetonide, preservative free, 1 mg	20	$6,623	None
Extended exam of the back part of the eye with optic nerve drawing	380	$5,690	$13
Destruction of growth of retina using a laser	12	$5,551	$463
1d and 2d ultrasound scan of eye tissue and structures	31	$3,074	$81
2d ultrasound scan of eye tissue and structures	47	$2,866	$42
Return visit (30+ min)	20	$1,328	$66
Extended exam of the back part of the eye with retinal drawing	50	$1,143	$22
Short return visit	16	$454	$28

2019: 31 services

Sort by

Original Medicare services billed in 2019

Injection, aflibercept, 1 mg	257	$2,409,702	None
Injection, ranibizumab, 0.1 mg	126	$864,037	None
Injection of drug into eye	669	$304,804	$90
Established patient complete exam of visual system	1,740	$238,285	$100
Imaging of retina	2,192	$212,273	$34
Injection, dexamethasone, intravitreal implant, 0.1 mg	43	$132,684	None
Established patient problem focused exam of visual system	765	$117,859	$74
Compounded drug, not otherwise classified	258	$71,521	None
New patient complete exam of visual system	494	$58,396	$118
Removal of membrane of retina with removal of internal limiting membrane of retina	29	$31,991	$1,000
Photography of the retina	642	$30,678	$42
Exam of retinal blood vessels using a special camera after injection of a dye	272	$23,132	$82
Injection, verteporfin, 0.1 mg	11	$14,215	None
Removal of eye fluid (vitreous) between lens and retina	17	$13,118	$772
Destruction of leaking blood vessels of retina using laser	27	$10,830	$301
Destruction of growth of retina using a laser	20	$10,636	$462
2d ultrasound scan of eye tissue and structures	128	$8,945	$50
Injection, triamcinolone acetonide, preservative free, 1 mg	31	$7,309	None
New patient visit (45+ min)	51	$7,025	$138
Destruction of vascular growth between retina and sclera by photodynamic therapy	11	$2,792	$254
Imaging of optic nerve	72	$2,624	$32
Injection, bevacizumab, 10 mg	33	$2,600	None
Exam of retinal blood vessels and blood vessels between the white part of eye and retina using a special camera after injection of a dye	11	$2,143	$195
Short return visit	33	$1,882	$38
Removal of eye fluid	15	$1,501	$94
Exam of visual field with extended testing	28	$1,420	$51
Extended exam involving color vision testing	25	$1,303	$47
Measurement of retinal and optic nerve function targeting multiple separate locations	15	$1,120	$75
Short return visit (20+ min)	18	$1,071	$59
Return visit (30+ min)	11	$1,050	$95
Examination of eye by ophthalmoscope with retinal drawing	14	$639	$25

2018: 25 services

Sort by

Original Medicare services billed in 2018

Injection, aflibercept, 1 mg	258	$2,420,534	None
Injection, ranibizumab, 0.1 mg	129	$996,559	None
Injection of drug into eye	734	$324,960	$90
Imaging of retina	2,375	$230,957	$35
Established patient complete exam of visual system	1,692	$226,481	$97
Injection, dexamethasone, intravitreal implant, 0.1 mg	60	$154,989	None
Established patient problem focused exam of visual system	687	$106,941	$73
Compounded drug, not otherwise classified	321	$80,301	None
New patient complete exam of visual system	656	$79,565	$121
Photography of the retina	793	$44,857	$48
Exam of retinal blood vessels using a special camera after injection of a dye	413	$32,652	$76
Removal of membrane of retina with removal of internal limiting membrane of retina	28	$30,139	$1,005
Destruction of leaking blood vessels of retina using laser	47	$23,230	$298
Removal of eye fluid (vitreous) between lens and retina	22	$17,623	$766
2d ultrasound scan of eye tissue and structures	172	$17,053	$61
Destruction of eye fluid (vitreous) between lens and retina and all of retina using a laser	18	$16,543	$871
Destruction of growth of retina using a laser	25	$14,283	$461
Injection, triamcinolone acetonide, preservative free, 1 mg	24	$5,532	None
Recording of retinal electrical responses to external stimuli	30	$3,837	$128
Imaging of optic nerve	108	$3,781	$31
Extended exam involving color vision testing	39	$2,621	$49
Exam of visual field with extended testing	31	$1,680	$54
Nerve test	23	$1,470	$64
Injection, bevacizumab, 10 mg	16	$1,464	None
Short return visit	13	$816	$39

2017: 29 services

Sort by

Original Medicare services billed in 2017

Injection, aflibercept, 1 mg	228	$2,184,035	None
Injection, ranibizumab, 0.1 mg	151	$1,121,238	None
Injection of drug into eye	729	$324,485	$88
Imaging of retina	2,412	$228,311	$33
Established patient complete exam of visual system	1,665	$220,296	$94
Injection, dexamethasone, intravitreal implant, 0.1 mg	67	$159,682	None
Established patient problem focused exam of visual system	670	$94,560	$68
Compounded drug, not otherwise classified	335	$84,875	None
New patient complete exam of visual system	717	$82,319	$115
Photography of the retina	853	$56,371	$58
Exam of retinal blood vessels using a special camera after injection of a dye	468	$33,212	$69
Removal of membrane of retina with removal of internal limiting membrane of retina	31	$29,642	$956
Destruction of leaking blood vessels of retina using laser	50	$26,906	$292
Injection, verteporfin, 0.1 mg	17	$20,581	None
2d ultrasound scan of eye tissue and structures	157	$18,588	$75
Destruction of eye fluid (vitreous) between lens and retina and all of retina using a laser	19	$17,536	$877
Destruction of growth of retina using a laser	33	$17,478	$448
Removal of eye fluid (vitreous) between lens and retina	17	$14,149	$786
Injection of synthetic eye fluid	11	$6,630	$603
Injection, triamcinolone acetonide, preservative free, 1 mg	25	$4,759	None
Destruction of vascular growth between retina and sclera by photodynamic therapy	15	$3,790	$253
Imaging of optic nerve	88	$3,501	$31
Recording of retinal electrical responses to external stimuli	20	$2,687	$128
Extended exam involving color vision testing	37	$2,660	$47
Exam of visual field with extended testing	27	$1,477	$55
Short return visit	22	$1,459	$36
Removal of eye fluid	18	$1,439	$76
Injection, bevacizumab, 10 mg	19	$1,382	None
Nerve test	11	$1,298	$118

2016: 34 services

Sort by

Original Medicare services billed in 2016

Injection, aflibercept, 1 mg	198	$1,925,604	None
Injection, ranibizumab, 0.1 mg	188	$1,397,448	None
Injection of drug into eye	736	$314,800	$88
Imaging of retina	2,740	$284,564	$37
Established patient complete exam of visual system	1,657	$212,621	$94
Injection, dexamethasone, intravitreal implant, 0.1 mg	64	$126,392	None
Established patient problem focused exam of visual system	692	$91,482	$70
New patient complete exam of visual system	782	$90,431	$116
Exam of retinal blood vessels using a special camera after injection of a dye	494	$85,067	$92
Compounded drug, not otherwise classified	323	$74,257	None
Removal of membrane of retina with removal of internal limiting membrane of retina	28	$29,072	$969
Destruction of leaking blood vessels of retina using laser	45	$24,330	$290
2d ultrasound scan of eye tissue and structures	160	$20,199	$79
Injection, verteporfin, 0.1 mg	12	$18,025	None
Destruction of growth of retina using a laser	35	$17,469	$448
Destruction of eye fluid (vitreous) between lens and retina and all of retina using a laser	17	$15,634	$869
Removal of eye fluid (vitreous) between lens and retina	20	$15,427	$735
Photocoagulation treatment to prevent detachment of retina	24	$11,936	$442
Removal of membrane of retina	11	$11,040	$1,004
Injection of synthetic eye fluid	13	$8,356	$597
Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye	18	$6,532	$218
Imaging of optic nerve	115	$5,521	$37
Injection, triamcinolone acetonide, preservative free, 1 mg	21	$4,620	None
Photography of the retina	60	$4,224	$68
Destruction of vascular growth between retina and sclera by photodynamic therapy	12	$3,475	$248
Extended exam involving color vision testing	50	$3,306	$48
Recording of retinal electrical responses to external stimuli	23	$3,054	$133
Short return visit	15	$1,973	$37
Nerve test	15	$1,769	$118
Removal of eye fluid	18	$1,614	$81
Exam of visual field with extended testing	29	$1,594	$53
Injection of drug or substance into membrane covering eyeball	15	$1,304	$77
Injection, bevacizumab, 10 mg	15	$1,052	None
Injection, triamcinolone acetonide, not otherwise specified, 10 mg	16	$42	None

2015: 29 services

Sort by

Original Medicare services billed in 2015

Injection, ranibizumab, 0.1 mg	239	$1,730,201	None
Injection, aflibercept, 1 mg	191	$1,609,108	None
Injection of drug into eye	715	$315,998	$88
Imaging of retina	2,646	$285,009	$38
Established patient complete exam of visual system	1,641	$222,299	$97
Injection, dexamethasone, intravitreal implant, 0.1 mg	76	$148,983	None
New patient complete exam of visual system	725	$86,672	$120
Exam of retinal blood vessels using a special camera after injection of a dye	485	$84,798	$92
Established patient problem focused exam of visual system	570	$75,871	$72
Destruction of leaking blood vessels of retina using laser	48	$56,407	$855
Unclassified biologics	228	$35,476	None
Compounded Drug, Not Otherwise Classified	238	$32,248	$53
Removal of membrane of retina with removal of internal limiting membrane of retina	26	$27,085	$1,003
Removal of eye fluid (vitreous) between lens and retina	28	$21,796	$778
Destruction of eye fluid (vitreous) between lens and retina and all of retina using a laser	21	$20,449	$889
2d ultrasound scan of eye tissue and structures	151	$18,853	$80
Removal of membrane of retina	17	$16,962	$998
Destruction of growth of retina using a laser	27	$13,836	$446
Photocoagulation treatment to prevent detachment of retina	27	$12,877	$415
Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye	22	$8,189	$215
Photography of the retina	62	$4,158	$65
Imaging of optic nerve	86	$3,934	$38
Recording of retinal electrical responses to external stimuli	25	$3,389	$130
Injection, triamcinolone acetonide, preservative free, 1 mg	12	$2,329	None
Exam of visual field with extended testing	41	$2,219	$53
Extended exam involving color vision testing	28	$1,678	$49
Removal of eye fluid	18	$1,617	$81
Short return visit	20	$1,073	$37
Injection, bevacizumab, 10 mg	17	$1,025	None

2014: 30 services

Sort by

Original Medicare services billed in 2014

Injection, ranibizumab, 0.1 mg	313	$2,347,213	None
Injection, aflibercept, 1 mg	149	$1,187,146	None
Injection of drug into eye	668	$295,607	$82
Imaging of retina	2,621	$285,145	$38
Established patient complete exam of visual system	1,580	$222,056	$98
Exam of retinal blood vessels using a special camera after injection of a dye	534	$95,925	$90
New patient complete exam of visual system	751	$87,854	$117
Injection, dexamethasone, intravitreal implant, 0.1 mg	47	$75,531	None
Established patient problem focused exam of visual system	603	$66,346	$67
Destruction of leaking blood vessels of retina using laser	40	$61,786	$858
Removal of membrane of retina	32	$36,698	$1,147
Injection, bevacizumab, 10 mg	249	$36,630	None
Removal of membrane of retina with removal of internal limiting membrane of retina	23	$32,413	$1,247
Removal of eye fluid (vitreous) between lens and retina	31	$27,036	$845
Destruction of growth of retina using a laser	44	$25,456	$455
Destruction of eye fluid (vitreous) between lens and retina and all of retina using a laser	17	$23,521	$1,176
Injection, verteporfin, 0.1 mg	16	$21,806	None
2d ultrasound scan of eye tissue and structures	140	$17,595	$80
Unclassified biologics	181	$15,508	None
Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye	31	$11,587	$203
Photocoagulation treatment to prevent detachment of retina	23	$11,059	$425
Destruction of vascular growth between retina and sclera by photodynamic therapy	17	$4,577	$241
Imaging of optic nerve	88	$3,675	$37
Photography of the retina	47	$3,216	$67
Injection, triamcinolone acetonide, preservative free, 1 mg	15	$2,552	None
Recording of retinal electrical responses to external stimuli	13	$1,725	$133
Exam of visual field with extended testing	33	$1,695	$51
Short return visit	23	$1,098	$34
Extended exam involving color vision testing	13	$637	$49
Examination of eye by ophthalmoscope with retinal drawing	20	$490	$21

2013: 35 services

Sort by

Original Medicare services billed in 2013

Injection, ranibizumab, 0.1 mg	329	$2,430,266	None
Injection, aflibercept, 1 mg	157	$1,353,443	None
Injection of drug into eye	649	$286,916	$81
Imaging of retina	2,408	$259,767	$38
Established patient complete exam of visual system	1,486	$208,635	$98
Exam of retinal blood vessels using a special camera after injection of a dye	504	$92,474	$93
New patient complete exam of visual system	744	$88,541	$119
Established patient problem focused exam of visual system	530	$59,355	$71
Injection, dexamethasone, intravitreal implant, 0.1 mg	35	$56,852	None
Destruction of leaking blood vessels of retina using laser	47	$56,732	$834
Removal of membrane of retina	40	$45,575	$1,139
Unclassified drugs	13	$42,674	None
Destruction of eye fluid (vitreous) between lens and retina and all of retina using a laser	25	$33,720	$1,204
Unclassified biologics	173	$30,314	None
Destruction of growth of retina using a laser	55	$28,341	$443
Removal of membrane of retina with removal of internal limiting membrane of retina	20	$25,960	$1,180
Injection, verteporfin, 0.1 mg	15	$20,899	None
Removal of eye fluid (vitreous) between lens and retina	22	$19,577	$816
2d ultrasound scan of eye tissue and structures	155	$18,103	$80
Repair of detached retina with drainage and removal of eye fluid between lens and retina	11	$14,423	$1,311
Photography of the retina	196	$13,049	$62
Injection, bevacizumab, 10 mg	123	$11,912	None
Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye	36	$10,995	$180
Photocoagulation treatment to prevent detachment of retina	23	$10,902	$436
Destruction of vascular growth between retina and sclera by photodynamic therapy	15	$4,181	$246
Injection, triamcinolone acetonide, preservative free, 1 mg	15	$2,673	None
Recording of retinal electrical responses to external stimuli	14	$2,192	$146
Imaging of optic nerve	57	$2,192	$38
Short return visit	26	$1,347	$36
Removal of eye fluid	13	$1,259	$97
Injection of drug or substance into membrane covering eyeball	16	$1,252	$74
Exam of visual field with extended testing	19	$1,131	$57
New patient problem focused exam of visual system	18	$1,100	$61
Examination of eye by ophthalmoscope with retinal drawing	17	$393	$20
Injection, triamcinolone acetonide, not otherwise specified, 10 mg	18	$44	None

Medicaid work

$42,765 in 2024

Medicaid paid $42,765 for 1,380 billed services this clinician did in 2024, up to 91 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Sort by

Largest Medicaid services in 2024

Intravitreal injection of a pharmacologic agent (separate procedure)	276	$27,249
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina	667	$8,256
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST	393	$6,175
New patient visit (45+ min)	17	$632
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient	27	$452

Sort by

Medicaid work by year

2024	1,380	5	91	$42,765
2023	2,069	6	94	$79,463
2022	1,728	6	82	$53,487
2021	1,154	5	46	$50,536
2020	1,063	5	60	$55,286
2019	1,117	4	50	$56,159
2018	1,605	7	64	$75,211

See the largest Medicaid services in earlier years

2023

Sort by

Largest Medicaid services in 2023

Intravitreal injection of a pharmacologic agent (separate procedure)	449	$43,116
Injection, bevacizumab, 10 mg	187	$12,163
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST	454	$12,025
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina	926	$11,442
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient	40	$647
Bilateral extended ophthalmoscopy with drawing of optic nerve, with interpretation and report	13	$70

2022

Sort by

Largest Medicaid services in 2022

Intravitreal injection of a pharmacologic agent (separate procedure)	299	$24,017
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient	405	$12,446
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina	724	$7,739
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST	166	$4,741
Injection, bevacizumab, 10 mg	122	$3,829
New patient visit (45+ min)	12	$716

2021

Sort by

Largest Medicaid services in 2021

Intravitreal injection of a pharmacologic agent (separate procedure)	217	$18,805
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina	464	$10,359
Injection, bevacizumab, 10 mg	107	$8,267
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST	197	$7,925
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient	169	$5,180

2020

Sort by

Largest Medicaid services in 2020

Intravitreal injection of a pharmacologic agent (separate procedure)	206	$29,864
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina	470	$9,199
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient	196	$7,064
Injection, bevacizumab, 10 mg	88	$6,265
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST	103	$2,894

2019

Sort by

Largest Medicaid services in 2019

Intravitreal injection of a pharmacologic agent (separate procedure)	242	$28,501
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient	249	$13,174
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina	521	$11,653
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST	105	$2,831

2018

Sort by

Largest Medicaid services in 2018

Intravitreal injection of a pharmacologic agent (separate procedure)	384	$44,314
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina	700	$13,049
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient	266	$10,755
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST	141	$3,277
Injection, bevacizumab, 10 mg	49	$2,937
FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT	49	$649
Compounded drug, not otherwise classified	16	$231

Drugs they prescribed that Part D paid

$135,944

Pharmacies billed $135,944 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 1,324) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.

845 generic and 479 brand-name prescriptions · $135,944 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Cyclosporine	40	$10,511	$263
Lumigan	24	$6,960	$290
Simbrinza	35	$6,955	$199
Combigan	21	$6,877	$327
Prolensa	18	$6,258	$348

See all 26 drugs

Sort by

Every Part D drug this clinician prescribed

Cyclosporine	40	$10,511	$263
Lumigan	24	$6,960	$290
Simbrinza	35	$6,955	$199
Combigan	21	$6,877	$327
Prolensa	18	$6,258	$348
Prednisolone Acetate	130	$5,312	$41
Brimonidine	101	$5,038	$50
Vyzulta	11	$4,550	$414
Brimonidine Tartrate-Timolol	32	$3,964	$124
Loteprednol Etabonate	13	$2,932	$226
Brinzolamide	14	$2,884	$206
Bromfenac	18	$2,681	$149
Difluprednate	17	$2,385	$140
Ketorolac Tromethamine	151	$2,358	$16
Latanoprost	230	$1,387	$6
Dorzolamide-Timolol	86	$1,265	$15
Atropine Sulfate	34	$979	$29
Moxifloxacin	42	$949	$23
Travoprost	13	$765	$59
Eplerenone	14	$635	$45
Timolol Maleate	44	$388	$9
Dorzolamide	32	$379	$12
Ofloxacin	36	$345	$10
Spironolactone	34	$290	$9
Neomycin-Polymyxin-Dexameth	32	$283	$9
Erythromycin	11	$99	$9

Year by year

Sort by

Part D prescribing by year

2024	1,324	344	0% (0)	36%	$135,944
2023	1,485	375	None	38%	$234,955
2022	1,855	412	None	40%	$231,335
2021	1,959	405	None	44%	$261,956
2020	1,868	394	None	47%	$295,708
2019	1,886	416	None	54%	$352,446
2018	1,901	456	None	62%	$399,206
2017	1,818	426	None	63%	$228,112
2016	2,122	445	1% (12)	62%	$212,934
2015	1,949	426	1% (13)	63%	$185,622
2014	2,090	444	None	65%	$189,510
2013	2,149	490	1% (12)	61%	$171,047

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 27 drugs

Sort by

Part D drugs prescribed in 2023

Eylea	16	$35,459	$2,216
Prolensa	48	$22,153	$462
Restasis	17	$13,973	$822
Combigan	42	$12,061	$287
Prednisolone Acetate	143	$7,670	$54
Simbrinza	32	$7,478	$234
Lumigan	20	$6,857	$343
Difluprednate	34	$6,670	$196
Brimonidine Tartrate-Timolol	27	$6,501	$241
Alphagan P	18	$5,901	$328
Ketorolac Tromethamine	174	$5,331	$31
Brimonidine	115	$4,693	$41
Cyclosporine	12	$4,184	$349
Travoprost	11	$3,095	$281
Latanoprost	216	$2,802	$13
Dorzolamide-Timolol	93	$2,248	$24
Moxifloxacin	38	$1,626	$43
Timolol Maleate	94	$1,229	$13
Tobramycin-Dexamethasone	12	$1,123	$94
Eplerenone	16	$1,121	$70
Atropine Sulfate	19	$866	$46
Spironolactone	23	$769	$33
Dorzolamide	37	$763	$21
Neomycin-Polymyxin-Dexameth	37	$574	$16
Ofloxacin	20	$278	$14
Ciprofloxacin	12	$179	$15
Erythromycin	17	$139	$8

2022: 26 drugs

Sort by

Part D drugs prescribed in 2022

Restasis	49	$40,521	$827
Eylea	17	$31,347	$1,844
Prolensa	55	$23,862	$434
Alphagan P	49	$12,531	$256
Lumigan	30	$11,841	$395
Simbrinza	49	$10,213	$208
Combigan	32	$9,888	$309
Prednisolone Acetate	200	$8,086	$40
Ketorolac Tromethamine	234	$5,536	$24
Difluprednate	30	$5,392	$180
Travoprost	19	$4,752	$250
Brimonidine	134	$3,725	$28
Latanoprost	268	$3,501	$13
Dorzolamide-Timolol	96	$2,590	$27
Eplerenone	18	$2,439	$135
Bepotastine Besilate	16	$2,356	$147
Dorzolamide	58	$1,520	$26
Timolol Maleate	91	$1,094	$12
Erythromycin	67	$762	$11
Spironolactone	46	$637	$14
Ofloxacin	45	$560	$12
Moxifloxacin	19	$559	$29
Atropine Sulfate	11	$541	$49
Neomycin-Polymyxin-Dexameth	23	$325	$14
Ciprofloxacin	21	$285	$14
Olopatadine	11	$232	$21

2021: 28 drugs

Sort by

Part D drugs prescribed in 2021

Eylea	22	$40,404	$1,837
Combigan	83	$24,798	$299
Restasis	33	$24,719	$749
Prolensa	41	$17,043	$416
Alphagan P	56	$14,984	$268
Xiidra	13	$12,268	$944
Prednisolone Acetate	229	$10,587	$46
Travoprost	38	$9,735	$256
Simbrinza	45	$8,891	$198
Lumigan	28	$8,594	$307
Durezol	37	$8,220	$222
Ketorolac Tromethamine	242	$8,135	$34
Ilevro	15	$6,458	$431
Bepreve	18	$4,634	$257
Brimonidine	124	$4,295	$35
Latanoprost	259	$3,410	$13
Dorzolamide	83	$2,873	$35
Dorzolamide-Timolol	68	$2,782	$41
Eplerenone	18	$2,014	$112
Timolol Maleate	108	$1,689	$16
Acetazolamide	18	$1,549	$86
Erythromycin	75	$872	$12
Olopatadine	30	$805	$27
Moxifloxacin	23	$654	$28
Neomycin-Polymyxin-Dexameth	43	$634	$15
Ofloxacin	25	$513	$21
Spironolactone	36	$508	$14
Ciprofloxacin	17	$172	$10

2020: 31 drugs

Sort by

Part D drugs prescribed in 2020

Eylea	24	$80,653	$3,361
Restasis	38	$27,682	$728
Lucentis	12	$25,705	$2,142
Combigan	61	$17,423	$286
Bepreve	40	$13,551	$339
Lumigan	38	$9,310	$245
Prednisolone Acetate	231	$9,148	$40
Alphagan P	35	$9,044	$258
Durezol	42	$8,390	$200
Simbrinza	44	$8,086	$184
Travoprost	42	$7,000	$167
Brimonidine	128	$6,225	$49
Travatan Z	22	$6,098	$277
Ilevro	12	$6,028	$502
Prolensa	14	$5,017	$358
Loteprednol Etabonate	25	$4,506	$180
Pazeo	18	$4,341	$241
Eplerenone	24	$4,029	$168
Ketorolac Tromethamine	167	$3,869	$23
Latanoprost	233	$2,744	$12
Dorzolamide-Timolol	58	$2,486	$43
Dorzolamide	65	$1,713	$26
Timolol Maleate	95	$1,679	$18
Olopatadine	39	$1,454	$37
Moxifloxacin	18	$873	$48
Erythromycin	59	$710	$12
Pilocarpine	11	$697	$63
Neomycin-Polymyxin-Dexameth	39	$602	$15
Ciprofloxacin	53	$555	$10
Spironolactone	43	$520	$12
Ofloxacin	33	$432	$13

2019: 30 drugs

Sort by

Part D drugs prescribed in 2019

Eylea	32	$86,414	$2,700
Lucentis	19	$43,501	$2,290
Restasis	57	$37,618	$660
Avastin	13	$17,778	$1,368
Ilevro	52	$16,566	$319
Travatan Z	55	$15,221	$277
Durezol	60	$12,244	$204
Lumigan	46	$11,381	$247
Alphagan P	45	$11,097	$247
Simbrinza	50	$9,657	$193
Combigan	44	$8,709	$198
Prednisolone Acetate	217	$8,398	$39
Brimonidine	135	$8,060	$60
Bepreve	30	$7,891	$263
Pazeo	37	$7,095	$192
Lotemax	18	$4,542	$252
Azopt	14	$4,377	$313
Eplerenone	33	$4,109	$125
Ketorolac Tromethamine	124	$3,930	$32
Latanoprost	232	$3,488	$15
Nevanac	12	$3,250	$271
Dorzolamide	85	$2,131	$25
Dorzolamide-Timolol	54	$1,936	$36
Bacitracin	11	$984	$89
Neomycin-Polymyxin-Dexameth	46	$714	$16
Timolol Maleate	82	$679	$8
Erythromycin	60	$677	$11
Ofloxacin	32	$604	$19
Spironolactone	39	$466	$12
Ciprofloxacin	25	$355	$14

2018: 34 drugs

Sort by

Part D drugs prescribed in 2018

Eylea	32	$80,653	$2,520
Lucentis	23	$51,410	$2,235
Restasis	68	$42,039	$618
Avastin	41	$35,823	$874
Ilevro	68	$18,298	$269
Azopt	57	$16,952	$297
Alphagan P	80	$15,322	$192
Combigan	79	$14,829	$188
Nevanac	51	$14,456	$283
Pazeo	56	$10,273	$183
Brimonidine	120	$10,136	$84
Prednisolone Acetate	223	$9,194	$41
Lumigan	45	$8,828	$196
Travatan Z	30	$8,300	$277
Durezol	43	$7,426	$173
Eplerenone	36	$5,656	$157
Prolensa	11	$3,869	$352
Lotemax	16	$3,628	$227
Simbrinza	19	$3,382	$178
Bromfenac	14	$3,356	$240
Latanoprost	186	$2,359	$13
Ketorolac Tromethamine	60	$1,822	$30
Dorzolamide	64	$1,556	$24
Acetazolamide	15	$1,446	$96
Tobramycin-Dexamethasone	13	$1,430	$110
Bacitracin	14	$1,224	$87
Moxifloxacin	16	$987	$62
Dorzolamide-Timolol	37	$834	$23
Neomycin-Polymyxin-Dexameth	48	$719	$15
Timolol Maleate	72	$634	$9
Spironolactone	40	$589	$15
Erythromycin	52	$537	$10
Ciprofloxacin	32	$386	$12
Ofloxacin	19	$325	$17

2017: 27 drugs

Sort by

Part D drugs prescribed in 2017

Restasis	70	$37,664	$538
Nevanac	77	$19,330	$251
Alphagan P	83	$16,054	$193
Combigan	92	$15,991	$174
Travatan Z	56	$14,191	$253
Simbrinza	79	$11,682	$148
Ilevro	48	$11,649	$243
Brimonidine	102	$11,199	$110
Lumigan	47	$8,767	$187
Prednisolone Acetate	201	$8,519	$42
Pazeo	50	$8,510	$170
Durezol	37	$5,985	$162
Prolensa	23	$5,395	$235
Eplerenone	36	$4,765	$132
Azopt	15	$3,997	$266
Pataday	21	$3,509	$167
Dorzolamide	126	$2,942	$23
Ketorolac Tromethamine	48	$2,045	$43
Vigamox	13	$2,031	$156
Latanoprost	153	$1,941	$13
Timolol Maleate	92	$813	$9
Dorzolamide-Timolol	30	$808	$27
Neomycin-Polymyxin-Dexameth	45	$649	$14
Erythromycin	44	$540	$12
Ciprofloxacin	49	$515	$11
Omega-3 Acid Ethyl Esters	11	$359	$33
Spironolactone	20	$310	$16

2016: 28 drugs

Sort by

Part D drugs prescribed in 2016

Nevanac	108	$25,764	$239
Restasis	52	$23,072	$444
Combigan	100	$16,278	$163
Alphagan P	88	$14,671	$167
Travatan Z	63	$13,634	$216
Brimonidine	134	$11,369	$85
Ilevro	47	$11,196	$238
Prednisolone Acetate	239	$11,048	$46
Pazeo	60	$9,495	$158
Prolensa	39	$8,387	$215
Simbrinza	54	$7,178	$133
Lumigan	41	$6,935	$169
Durezol	40	$6,150	$154
Pataday	35	$5,612	$160
Lotemax	24	$4,405	$184
Bromfenac	16	$3,989	$249
Ketorolac Tromethamine	105	$3,883	$37
Azopt	13	$3,252	$250
Dorzolamide	135	$2,781	$21
Latanoprost	213	$2,632	$12
Vigamox	16	$2,419	$151
Timolol Maleate	130	$1,075	$8
Neomycin-Polymyxin-Dexameth	40	$667	$17
Dorzolamide-Timolol	31	$587	$19
Erythromycin	46	$574	$12
Ciprofloxacin	57	$574	$10
Omega-3 Acid Ethyl Esters	11	$485	$44
Hydrocodone-Acetaminophen	11	$41	$4

2015: 29 drugs

Sort by

Part D drugs prescribed in 2015

Nevanac	160	$36,987	$231
Restasis	62	$23,259	$375
Prednisolone Acetate	265	$13,898	$52
Combigan	81	$11,440	$141
Travatan Z	69	$11,077	$161
Alphagan P	67	$10,311	$154
Lotemax	42	$8,860	$211
Brimonidine	111	$8,381	$76
Prolensa	32	$6,865	$215
Pataday	39	$6,390	$164
Lumigan	34	$5,118	$151
Ketorolac Tromethamine	118	$4,286	$36
Durezol	27	$4,074	$151
Vigamox	22	$3,648	$166
Simbrinza	23	$2,717	$118
Azopt	12	$2,708	$226
Acuvail	11	$2,461	$224
Tobradex	12	$2,276	$190
Dorzolamide	102	$1,919	$19
Latanoprost	158	$1,768	$11
Tobramycin-Dexamethasone	16	$1,763	$110
Xalatan	12	$1,625	$135
Timolol Maleate	159	$1,358	$9
Acetazolamide	12	$1,086	$91
Neomycin-Polymyxin-Dexameth	36	$646	$18
Erythromycin	45	$591	$13
Ciprofloxacin	58	$571	$10
Dorzolamide-Timolol	29	$545	$19
Spironolactone	15	$113	$8

2014: 28 drugs

Sort by

Part D drugs prescribed in 2014

Nevanac	201	$34,964	$174
Restasis	62	$21,076	$340
Prednisolone Acetate	317	$17,846	$56
Travatan Z	94	$14,057	$150
Pataday	65	$11,043	$170
Alphagan P	94	$10,923	$116
Lumigan	71	$9,618	$135
Brimonidine	95	$7,466	$79
Combigan	52	$6,689	$129
Ketorolac Tromethamine	184	$5,822	$32
Lotemax	34	$5,732	$169
Bromfenac	41	$5,618	$137
Durezol	36	$5,004	$139
Prolensa	19	$3,740	$197
Azopt	23	$3,596	$156
Tobramycin-Dexamethasone	12	$2,254	$188
Vigamox	18	$2,070	$115
Dorzolamide	75	$1,772	$24
Latanoprost	122	$1,735	$14
Gatifloxacin	13	$1,216	$94
Timolol Maleate	118	$1,050	$9
Dorzolamide-Timolol	35	$775	$22
Ciprofloxacin	59	$664	$11
Erythromycin	46	$636	$14
Propranolol Hcl Er	12	$500	$42
Spironolactone	30	$279	$9
Neomycin-Polymyxin-Dexameth	13	$248	$19
Ofloxacin	17	$168	$10

2013: 32 drugs

Sort by

Part D drugs prescribed in 2013

Nevanac	91	$15,218	$167
Bromfenac	87	$13,091	$150
Alphagan P	104	$12,995	$125
Travatan Z	73	$10,941	$150
Bromday	49	$10,463	$214
Lumigan	77	$10,171	$132
Restasis	28	$9,312	$333
Brimonidine	115	$8,766	$76
Pataday	44	$7,060	$160
Prednisolone Acetate	263	$6,333	$24
Zymaxid	50	$6,047	$121
Combigan	60	$6,024	$100
Patanol	36	$4,953	$138
Lotemax	30	$4,532	$151
Tobradex	24	$4,304	$179
Besivance	38	$4,023	$106
Azopt	29	$3,992	$138
Tobramycin-Dexamethasone	27	$3,924	$145
Durezol	28	$3,206	$115
Ketorolac Tromethamine	136	$2,996	$22
Vigamox	22	$2,936	$133
Dorzolamide	76	$2,271	$30
Latanoprost	108	$2,055	$19
Azasite	19	$1,843	$97
Ciprofloxacin	85	$1,159	$14
Neomycin-Polymyxin-Dexameth	53	$986	$19
Erythromycin	54	$837	$16
Timolol Maleate	89	$809	$9
Dorzolamide-Timolol	26	$732	$28
Propranolol	12	$281	$23
Spironolactone	26	$220	$8
Ofloxacin	31	$205	$7

Money from drug and device companies

$17,012 in 2025

Sort by

Industry payments by year

2025	13	34	$15,592	$17,012
2024	15	58	$139,327	$141,884
2023	19	48	$40,181	$41,594
2022	18	48	$48,381	$50,735
2021	12	25	$55,877	$56,215
2020	12	37	$49,470	$50,809
2019	21	57	$44,329	$47,979

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

Avirmax Biopharma, Inc
Published ownership
$0
Held by this doctor · 2025 · This Option Grant Shall Be Subject To the Terms and Conditions of the Avirmaxs Stock Option Plan and Stock Option Agreement, Including Vesting Requirements. · amount invested $1,900

Published ownership or investment in a drug or device company. This is not proof that care is biased.

A payment is not proof that care is biased.

Sort by

Payments by company

Apellis Pharmaceuticals	Syfovre	$3,568	5 payments Meals for Syfovre · 2025-07-31 · $153 Consulting for Syfovre · 2025-07-02 · $2,172 Consulting for Syfovre · 2025-07-02 · $543 Meals for Syfovre · 2025-06-23 · $157 Consulting for Syfovre · 2025-03-04 · $543
Boehringer Ingelheim International GmbH	None	$2,850	3 payments Consulting · 2025-04-03 · $950 Consulting · 2025-04-03 · $950 Consulting · 2025-04-03 · $950
Amgen	Pavblu	$2,636	1 payment Consulting for Pavblu · 2025-05-14 · $2,636
Bausch & Lomb Americas	None	$2,548	2 payments Consulting · 2025-10-16 · $2,500 Meals · 2025-10-16 · $48
Regeneron Pharmaceuticals	Eylea	$1,175	3 payments Consulting for Eylea · 2025-09-18 · $1,105 Meals for Eylea Hd · 2025-09-12 · $45 Meals for Eylea Hd · 2025-05-09 · $25
Alcon Vision	None	$1,000	1 payment Consulting · 2025-06-20 · $1,000

See all 34 published payments

Sort by

Every published payment

Abbvie	Meals · 2025-12-19	Ozurdex	$6
Abbvie	Meals · 2025-12-03	Ozurdex	$17
Abbvie	Consulting · 2025-11-19	None	$769
Bausch & Lomb Americas	Consulting · 2025-10-16	None	$2,500
Bausch & Lomb Americas	Meals · 2025-10-16	None	$48
Abbvie	Meals · 2025-09-18	Ozurdex	$21
Regeneron Pharmaceuticals	Consulting · 2025-09-18	Eylea	$1,105
Ocular Therapeutix	Meals · 2025-09-13	Dextenza	$59
Regeneron Pharmaceuticals	Meals · 2025-09-12	Eylea Hd	$45
Sun Pharmaceutical Industries	Travel · 2025-09-12	None	$300
Abbvie	Meals · 2025-09-04	Ozurdex	$18
Neurotech Pharmaceuticals	Consulting · 2025-09-02	Encelto	$475
Abbvie	Meals · 2025-08-06	Ozurdex	$6
Apellis Pharmaceuticals	Meals · 2025-07-31	Syfovre	$153
Ocular Therapeutix	Meals · 2025-07-30	Dextenza	$269
Abbvie	Meals · 2025-07-16	Ozurdex	$15
Abbvie	Meals · 2025-07-10	Ozurdex	$9
Apellis Pharmaceuticals	Consulting · 2025-07-02	Syfovre	$2,172
Apellis Pharmaceuticals	Consulting · 2025-07-02	Syfovre	$543
Apellis Pharmaceuticals	Meals · 2025-06-23	Syfovre	$157
Alcon Vision	Consulting · 2025-06-20	None	$1,000
Genentech USA	Meals · 2025-05-28	Vabysmo	$26
Amgen	Consulting · 2025-05-14	Pavblu	$2,636
Regeneron Pharmaceuticals	Meals · 2025-05-09	Eylea Hd	$25
Neurotech Pharmaceuticals	Meals · 2025-05-08	None	$34
Ocular Therapeutix	Meals · 2025-04-26	Dextenza	$157
Abbvie	Meals · 2025-04-23	Ozurdex	$11
Boehringer Ingelheim International GmbH	Consulting · 2025-04-03	None	$950
Boehringer Ingelheim International GmbH	Consulting · 2025-04-03	None	$950
Boehringer Ingelheim International GmbH	Consulting · 2025-04-03	None	$950
Glaukos	Consulting · 2025-04-02	None	$1,000
Abbvie	Meals · 2025-03-10	Ozurdex	$16
Apellis Pharmaceuticals	Consulting · 2025-03-04	Syfovre	$543
Novartis Pharmaceuticals	Meals · 2025-01-14	Xolair	$30

See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $141,884

Sort by

Payments by company in 2024

EyePoint Pharmaceuticals US	Eyp-1901	$102,767	4 payments Gift for Eyp-1901 · 2024-12-05 · $142 Consulting for Eyp-1901 · 2024-06-04 · $1,050 Consulting for Eyp-1901 · 2024-04-30 · $100,000 Consulting for Eyp-1901 · 2024-01-19 · $1,575
Genentech USA	Vabysmo	$8,694	7 payments Meals · 2024-05-04 · $150 Travel for Vabysmo · 2024-04-13 · $507 Consulting for Vabysmo · 2024-04-13 · $7,560 Meals for Vabysmo · 2024-04-13 · $234 Travel for Vabysmo · 2024-04-13 · $188 Meals for Vabysmo · 2024-04-11 · $31 Meals for Vabysmo · 2024-02-15 · $24
Regeneron Pharmaceuticals	Eylea Hd	$8,548	6 payments Consulting for Eylea Hd · 2024-10-10 · $1,105 Consulting for Eylea Hd · 2024-08-14 · $1,020 Consulting for Eylea Hd · 2024-08-14 · $510 Consulting for Eylea · 2024-05-24 · $2,210 Consulting for Eylea · 2024-03-01 · $529 Consulting for Eylea Hd · 2024-01-26 · $3,174
Apellis Pharmaceuticals	Syfovre	$6,008	5 payments Consulting for Syfovre · 2024-12-12 · $1,086 Consulting for Syfovre · 2024-12-12 · $2,172 Paid to speak or teach for Syfovre · 2024-07-10 · $2,172 Consulting for Syfovre · 2024-05-29 · $543 Meals for Syfovre · 2024-05-06 · $35
Regeneron Healthcare Solutions	Eylea Hd	$4,232	1 payment Consulting for Eylea Hd · 2024-02-23 · $4,232
Boehringer Ingelheim International GmbH	None	$3,575	2 payments Consulting · 2024-12-13 · $950 Consulting · 2024-12-13 · $2,625
Glaukos	None	$2,350	4 payments Consulting · 2024-12-19 · $500 Consulting · 2024-12-19 · $500 Consulting · 2024-08-14 · $1,000 Consulting · 2024-04-10 · $350
Abbvie	Ozurdex	$1,736	12 payments Consulting · 2024-12-16 · $1,200 Meals for Ozurdex · 2024-11-18 · $13 Meals for Ozurdex · 2024-11-08 · $17 Meals for Ozurdex · 2024-09-06 · $14 Meals for Ozurdex · 2024-08-01 · $7 Consulting · 2024-07-17 · $400 Meals for Ozurdex · 2024-06-12 · $12 Meals for Ozurdex · 2024-05-20 · $15 Meals for Ozurdex · 2024-05-10 · $12 Meals for Ozurdex · 2024-03-29 · $13 Meals for Ozurdex · 2024-03-08 · $16 Meals for Ozurdex · 2024-02-16 · $17
Bausch & Lomb Americas	Xipere	$1,191	5 payments Meals · 2024-10-18 · $130 Meals for Xipere · 2024-08-14 · $20 Consulting for Xipere · 2024-08-07 · $1,000 Meals for Vyzulta · 2024-06-04 · $31 Meals for Miebo · 2024-02-28 · $10
BioCryst Pharmaceuticals	None	$1,054	1 payment Consulting · 2024-08-14 · $1,054
Samsung Bioepis Co.	None	$810	1 payment Consulting · 2024-10-02 · $810
Ocular Therapeutix	Dextenza	$443	4 payments Meals for Dextenza · 2024-10-18 · $21 Meals for Dextenza · 2024-07-18 · $27 Meals for Dextenza · 2024-05-09 · $299 Meals for Dextenza · 2024-04-27 · $96
Alcon Vision	Constellation	$278	2 payments Meals for Constellation · 2024-12-22 · $148 Meals for Constellation · 2024-08-13 · $130
Sandoz	Cimerli	$185	3 payments Meals for Cimerli · 2024-06-11 · $93 Meals for Cimerli · 2024-05-07 · $47 Meals for Cimerli · 2024-05-03 · $45
Biogen	Byooviz	$13	1 payment Meals for Byooviz · 2024-02-28 · $13

2023: $41,594

Sort by

Payments by company in 2023

Regeneron Pharmaceuticals	Eylea	$9,971	8 payments Consulting for Eylea · 2023-11-02 · $2,000 Meals for Eylea · 2023-10-31 · $138 Consulting for Eylea · 2023-08-11 · $2,160 Consulting for Eylea · 2023-07-07 · $2,116 Meals for Eylea · 2023-05-10 · $96 Consulting for Eylea · 2023-05-05 · $265 Consulting for Eylea · 2023-05-05 · $2,116 Consulting for Eylea · 2023-01-05 · $1,080
Apellis Pharmaceuticals	Syfovre	$9,897	6 payments Consulting for Syfovre · 2023-12-15 · $1,086 Consulting · 2023-11-03 · $4,887 Meals for Syfovre · 2023-11-03 · $123 Consulting for Syfovre · 2023-07-25 · $1,086 Consulting · 2023-06-21 · $1,086 Consulting · 2023-06-08 · $1,629
Amgen	None	$7,203	3 payments Consulting · 2023-11-08 · $2,949 Consulting · 2023-11-08 · $3,932 Consulting · 2023-10-09 · $322
Sanofi US Services	None	$6,330	2 payments Consulting · 2023-04-22 · $6,228 Meals · 2023-04-22 · $102
EyePoint Pharmaceuticals US	Eyp-1901	$2,822	4 payments Gift · 2023-11-30 · $120 Consulting for Eyp-1901 · 2023-11-02 · $525 Consulting for Eyp-1901 · 2023-07-01 · $2,100 Meals for Yutiq · 2023-02-17 · $76
Kyowa Kirin	None	$2,800	1 payment Consulting · 2023-07-20 · $2,800
Boehringer Ingelheim International GmbH	None	$745	1 payment Consulting · 2023-09-28 · $745
Glaukos	None	$700	1 payment Consulting · 2023-07-05 · $700
Janssen Global Services	None	$370	1 payment Consulting · 2023-11-01 · $370
Genentech USA	Vabysmo	$172	7 payments Meals for Vabysmo · 2023-08-25 · $30 Meals for Vabysmo · 2023-08-15 · $19 Meals for Vabysmo · 2023-07-13 · $17 Meals for Vabysmo · 2023-05-18 · $30 Meals for Vabysmo · 2023-05-18 · $22 Meals for Vabysmo · 2023-03-10 · $31 Meals for Vabysmo · 2023-03-01 · $24
Regeneron Healthcare Solutions	Eylea	$167	2 payments Meals for Eylea · 2023-10-06 · $129 Meals for Eylea · 2023-07-05 · $38
AbbVie	Ozurdex	$108	5 payments Meals for Ozurdex · 2023-08-15 · $15 Meals for Ozurdex · 2023-06-16 · $24 Meals for Ozurdex · 2023-05-31 · $28 Meals for Ozurdex · 2023-03-13 · $16 Meals for Ozurdex · 2023-02-07 · $24
Mallinckrodt Hospital Products	Acthar	$100	1 payment Meals for Acthar · 2023-03-18 · $100
Astellas Pharma US	None	$99	1 payment Meals · 2023-08-22 · $99
Alexion Pharmaceuticals	None	$38	1 payment Meals · 2023-04-26 · $38
La Jolla Pharmaceutical	Giapreza	$22	1 payment Meals for Giapreza · 2023-02-17 · $22
Horizon Therapeutics plc	Tepezza	$20	1 payment Meals for Tepezza · 2023-03-24 · $20
Boston Scientific	Bodyguardian	$18	1 payment Meals for Bodyguardian · 2023-06-02 · $18
Ocular Therapeutix	Dextenza	$13	1 payment Meals for Dextenza · 2023-10-11 · $13

2022: $50,735

Sort by

Payments by company in 2022

Janssen Global Services	None	$8,609	5 payments Travel · 2022-11-02 · $219 Travel · 2022-11-02 · $230 Meals · 2022-11-02 · $69 Travel · 2022-11-02 · $171 Consulting · 2022-11-02 · $7,920
Genentech USA	Vabysmo	$5,546	8 payments Meals for Vabysmo · 2022-11-28 · $24 Meals · 2022-08-19 · $23 Meals · 2022-08-08 · $23 Travel for Vabysmo · 2022-05-19 · $595 Meals for Vabysmo · 2022-05-19 · $149 Paid to speak or teach for Vabysmo · 2022-05-19 · $3,930 Meals for Vabysmo · 2022-03-09 · $23 Paid to speak or teach for Susvimo · 2022-02-05 · $780
Apellis Pharmaceuticals	None	$5,454	2 payments Consulting · 2022-10-19 · $5,430 Meals · 2022-04-02 · $24
Boehringer Ingelheim Pharmaceuticals	None	$5,250	1 payment Consulting · 2022-02-15 · $5,250
EyePoint Pharmaceuticals US	Yutiq	$4,842	4 payments Consulting for Yutiq · 2022-09-02 · $1,700 Meals for Yutiq · 2022-07-15 · $167 Consulting for Yutiq · 2022-06-24 · $425 Consulting for Yutiq · 2022-05-13 · $2,550
Genentech	Lucentis	$4,060	2 payments Consulting for Lucentis · 2022-11-12 · $2,100 Consulting for Vabysmo · 2022-02-26 · $1,960
Regeneron Pharmaceuticals	Eylea	$3,277	3 payments Meals for Eylea · 2022-10-01 · $37 Consulting for Eylea · 2022-05-20 · $2,430 Consulting for Eylea · 2022-05-20 · $810
Regeneron Healthcare Solutions	Eylea	$3,174	1 payment Consulting for Eylea · 2022-08-26 · $3,174
Kyowa Kirin	None	$2,519	3 payments Consulting · 2022-11-17 · $2,250 Travel · 2022-10-03 · $125 Meals · 2022-10-02 · $144
Boehringer Ingelheim International GmbH	None	$2,345	2 payments Consulting · 2022-08-01 · $1,600 Consulting · 2022-05-25 · $745
Bausch & Lomb Americas	Doctors Allergy Formula	$1,818	3 payments Consulting · 2022-10-19 · $1,650 Meals · 2022-10-02 · $147 Meals for Doctors Allergy Formula · 2022-06-29 · $21
Pfizer	None	$1,460	1 payment Honoraria · 2022-01-14 · $1,460
Abbvie	Ozurdex	$920	8 payments Meals for Ozurdex · 2022-12-16 · $12 Meals for Ozurdex · 2022-11-21 · $14 Meals for Ozurdex · 2022-11-01 · $17 Meals for Ozurdex · 2022-08-31 · $17 Consulting · 2022-08-11 · $800 Meals for Ozurdex · 2022-06-29 · $28 Meals for Ozurdex · 2022-05-12 · $5 Meals for Ozurdex · 2022-02-25 · $27
Glaukos	Istent Inject W	$700	1 payment Consulting for Istent Inject W · 2022-08-17 · $700
Amgen	None	$643	1 payment Consulting · 2022-07-18 · $643
Grifols S.A.	None	$74	1 payment Consulting · 2022-09-29 · $74
Biogen	None	$28	1 payment Meals · 2022-11-30 · $28
Allergan	Ozurdex	$16	1 payment Meals for Ozurdex · 2022-03-14 · $16

2021: $56,215

Sort by

Payments by company in 2021

Grifols S.A.	None	$27,253	1 payment Consulting · 2021-02-01 · $27,253
Boehringer Ingelheim International GmbH	None	$11,255	4 payments Paid to speak or teach · 2021-06-22 · $398 Paid to speak or teach · 2021-06-21 · $4,726 Paid to speak or teach · 2021-04-12 · $3,151 Consulting · 2021-03-05 · $2,980
Regeneron Pharmaceuticals	Eylea	$8,640	5 payments Consulting for Eylea · 2021-12-17 · $540 Consulting for Eylea · 2021-11-05 · $1,080 Consulting for Eylea · 2021-02-26 · $1,080 Consulting for Eylea · 2021-01-29 · $3,240 Consulting for Eylea · 2021-01-29 · $2,700
Biogen	None	$3,400	1 payment Consulting · 2021-10-27 · $3,400
Amgen	None	$1,929	3 payments Consulting · 2021-12-01 · $643 Consulting · 2021-08-11 · $643 Consulting · 2021-04-19 · $643
Kala Pharmaceuticals	Eysuvis	$1,350	2 payments Consulting for Eysuvis · 2021-03-12 · $900 Consulting for Eysuvis · 2021-02-16 · $450
Glaukos	None	$1,050	1 payment Consulting · 2021-04-27 · $1,050
Bausch & Lomb a division of Bausch Health US	Vitesse	$1,019	2 payments Meals for Vitesse · 2021-11-23 · $19 Consulting · 2021-10-29 · $1,000
Alimera Sciences	Iluvien	$149	1 payment Meals for Iluvien · 2021-08-18 · $149
Mallinckrodt Hospital Products	Acthar	$93	1 payment Education for Acthar · 2021-02-09 · $93
Genentech USA	Susvimo	$42	2 payments Meals for Susvimo · 2021-10-22 · $22 Meals for Lucentis · 2021-09-20 · $20
EyePoint Pharmaceuticals US	Yutiq	$35	2 payments Meals for Yutiq · 2021-11-14 · $19 Meals for Yutiq · 2021-05-09 · $16

2020: $50,809

Sort by

Payments by company in 2020

Regeneron Pharmaceuticals	Eylea	$24,510	8 payments Consulting for Eylea · 2020-12-18 · $1,080 Consulting for Eylea · 2020-12-18 · $3,240 Consulting for Eylea · 2020-11-20 · $540 Consulting for Eylea · 2020-10-09 · $1,080 Consulting for Eylea · 2020-10-09 · $2,160 Consulting for Eylea · 2020-10-01 · $1,020 Consulting for Eylea · 2020-07-09 · $9,990 Consulting for Eylea · 2020-07-09 · $5,400
Boehringer Ingelheim Pharmaceuticals	None	$5,822	9 payments Travel · 2020-05-05 · $140 Consulting · 2020-05-05 · $4,720 Meals · 2020-05-05 · $35 Travel · 2020-02-22 · $630 Meals · 2020-02-22 · $53 Meals · 2020-02-22 · $16 Meals · 2020-02-22 · $92 Meals · 2020-02-22 · $16 Meals · 2020-02-22 · $121
Ocular Therapeutix	Dextenza	$3,400	3 payments Consulting for Dextenza · 2020-05-09 · $1,275 Consulting for Dextenza · 2020-05-09 · $850 Paid to speak or teach for Dextenza · 2020-04-07 · $1,275
Novartis Pharmaceuticals	Beovu	$3,329	3 payments Meals for Beovu · 2020-02-22 · $41 Consulting for Beovu · 2020-02-22 · $3,225 Meals for Beovu · 2020-02-22 · $64
EyePoint Pharmaceuticals US	Yutiq	$3,208	4 payments Consulting for Yutiq · 2020-12-01 · $800 Consulting for Yutiq · 2020-10-31 · $1,600 Meals for Dexycu · 2020-03-04 · $8 Consulting for Yutiq · 2020-02-06 · $800
Bausch & Lomb a division of Bausch Health US	Xipere	$2,375	2 payments Consulting for Xipere · 2020-02-21 · $2,250 Meals for Xipere · 2020-02-07 · $125
Thrombogenics	Jetrea	$2,250	2 payments Consulting for Jetrea · 2020-09-18 · $1,250 Consulting for Jetrea · 2020-01-21 · $1,000
Genentech USA	Lucentis	$1,815	1 payment Consulting for Lucentis · 2020-12-05 · $1,815
Glaukos	None	$1,400	1 payment Consulting · 2020-10-13 · $1,400
Horizon Therapeutics plc	None	$1,400	2 payments Consulting · 2020-09-30 · $700 Consulting · 2020-09-29 · $700
Allergan	None	$750	1 payment Consulting · 2020-01-01 · $750
Amgen	None	$550	1 payment Consulting · 2020-12-11 · $550

2019: $47,979

Sort by

Payments by company in 2019

Shire North American Group	Takhzyro	$9,628	5 payments Consulting for Takhzyro · 2019-07-28 · $8,500 Meals for Takhzyro · 2019-07-28 · $40 Meals for Takhzyro · 2019-07-28 · $25 Consulting · 2019-07-14 · $638 Consulting · 2019-06-12 · $425
Genentech	Lucentis	$8,525	6 payments Meals for Lucentis · 2019-05-18 · $239 Consulting for Lucentis · 2019-05-17 · $6,600 Travel for Lucentis · 2019-05-17 · $296 Travel for Lucentis · 2019-05-17 · $1,237 Travel for Lucentis · 2019-05-17 · $76 Meals for Lucentis · 2019-02-18 · $77
F. Hoffmann-La Roche AG	Lucentis	$5,764	4 payments Paid to speak or teach for Lucentis · 2019-09-30 · $3,038 Consulting for Non-Covered Product · 2019-04-28 · $1,960 Meals for Non-Covered Product · 2019-04-28 · $53 Paid to speak or teach for Lucentis · 2019-03-31 · $714
Aerie Pharmaceuticals	None	$4,163	5 payments Meals · 2019-10-12 · $42 Consulting · 2019-10-03 · $3,300 Meals · 2019-07-23 · $94 Meals · 2019-07-23 · $127 Consulting · 2019-02-06 · $600
Novartis Pharmaceuticals	Beovu	$3,704	6 payments Meals for Beovu · 2019-07-26 · $110 Consulting · 2019-04-27 · $3,360 Meals · 2019-04-27 · $76 Meals · 2019-03-22 · $125 Meals for Travatan Z · 2019-02-27 · $13 Meals for Beovu · 2019-02-09 · $21
Glaukos	None	$2,800	2 payments Honoraria · 2019-07-25 · $1,400 Honoraria · 2019-07-25 · $1,400
EyePoint Pharmaceuticals US	Yutiq	$2,468	2 payments Consulting for Yutiq · 2019-06-28 · $2,400 Meals for Yutiq · 2019-04-27 · $68
Allergan	Ozurdex	$2,312	4 payments Meals for Ozurdex · 2019-10-21 · $20 Meals for Ozurdex · 2019-09-11 · $42 Consulting for Ozurdex · 2019-09-11 · $1,125 Consulting for Ozurdex · 2019-01-01 · $1,125
Allergan	Ozurdex	$2,292	3 payments Consulting for Ozurdex · 2019-09-11 · $1,125 Meals for Ozurdex · 2019-09-11 · $42 Consulting for Ozurdex · 2019-01-01 · $1,125
Kala Pharmaceuticals	Inveltys	$1,838	3 payments Consulting · 2019-08-16 · $900 Consulting · 2019-04-04 · $900 Meals for Inveltys · 2019-01-21 · $38
Amgen	None	$1,650	1 payment Consulting · 2019-10-15 · $1,650
ThromboGenics	Jetrea	$1,000	1 payment Consulting for Jetrea · 2019-12-31 · $1,000
Boehringer Ingelheim Pharmaceuticals	None	$745	1 payment Consulting · 2019-12-04 · $745
Alcon Vision	Constellation	$310	3 payments Meals for Constellation · 2019-11-12 · $112 Meals for Constellation · 2019-07-25 · $121 Meals for Centurion · 2019-01-21 · $77
Boehringer Ingelheim International GmbH	None	$300	1 payment Consulting · 2019-08-01 · $300
Genentech USA	Lucentis	$220	2 payments Meals · 2019-10-11 · $172 Meals for Lucentis · 2019-02-09 · $48
Regeneron Healthcare Solutions	Eylea	$99	2 payments Meals for Eylea · 2019-07-28 · $21 Meals for Eylea · 2019-02-09 · $78
Ocular Therapeutix	Resure Sealant	$63	2 payments Meals for Resure Sealant · 2019-10-11 · $32 Meals for Dextenza · 2019-10-11 · $32
Stryker	Spirox - Latera	$52	1 payment Meals for Spirox - Latera · 2019-02-28 · $52
Eyevance Pharmaceuticals	Flarex	$37	1 payment Meals for Flarex · 2019-01-20 · $37
Alimera Sciences	Iluvien	$10	2 payments Meals for Iluvien · 2019-02-13 · $5 Meals for Iluvien · 2019-02-13 · $5

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2020	Their institution	$493,514
Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Masked Phase 3a Study To Assess Safety and Efficacy of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks in Patients With Neovascular Age Related Macular Degeneration Namd With Persistent Retinal Fluid · 2020	Their institution	$475,531
Boehringer Ingelheim Pharmaceuticals, Inc. · Ph2a Pom in Npdr Bi 1467335 Vs Plc 12 Wk · 2019	Their institution	$185,729
Genentech, Inc. · Va2 Phiii Rhine · 2020	Their institution	$181,809
Novartis Pharmaceuticals Corporation · A Two Year, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due To Diabetic Macular Edema · 2020	Their institution	$161,640
Novartis Pharmaceuticals Corporation · A Two Year, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due To Diabetic Macular Edema · 2019	Their institution	$153,800
Genentech, Inc. · Va2 Phiii Rhine · 2019	Their institution	$149,428
Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Masked Phase 3a Study To Assess Safety and Efficacy of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks in Patients With Neovascular Age Related Macular Degeneration Namd With Persistent Retinal Fluid · 2021	Their institution	$141,767
Aerie Pharmaceuticals, Inc. · A Multicenter, Open-Label, Safety and Proof-of-Concept Study To Assess Safety, Tolerability and Efficacy of Ar-1105 in Subjects With Macular Edema Due To Retinal Vein Occlusion (Rvo) · 2020	Their institution	$90,444
Boehringer Ingelheim Pharmaceuticals, Inc. · Ph2a Pom in Npdr Bi 1467335 Vs Plc 12 Wk · 2020	Their institution	$87,099
Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Masked Phase 3a Study To Assess Safety and Efficacy of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks in Patients With Neovascular Age Related Macular Degeneration Namd With Persistent Retinal Fluid · 2019	Their institution	$86,080
Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2019	Their institution	$75,874
Novartis Pharmaceuticals Corporation · A Two Year, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due To Diabetic Macular Edema · 2021	Their institution	$74,029
Grifols Biologicals LLC · A Double-Masked, Placebo-Controlled, Dose Ranging Study To Evaluate the Efficacy of Oral Akst4290 With Loading Doses of Aflibercept in Patients With Newly Diagnosed Neovascular Age-Related Macular Degeneration · 2021	Their institution	$70,733
Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2021	Their institution	$65,180
Aerie Pharmaceuticals, Inc. · A Study Assessing Ar-13503 Implant Alone and in Combination With Aflibercept in Subjects With Namd Or Dme · 2021	Their institution	$63,645
Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2021	Their institution	$59,776
Genentech, Inc. · Va2 Phiii Rhine · 2021	Their institution	$58,220
Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2021	Their institution	$48,115
Genentech, Inc. · Port Delivery System for Ranibizumab · 2020	Their institution	$44,608
Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2022	Their institution	$44,214
Alexion Pharmaceuticals, Inc. · A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (Alxn2040) in Patients With Geographic Atrophy (Ga) Secondary To Age Related Macular Degeneration (Amd) · 2023	Their institution	$38,101
Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal Regn910-3 in Patients With Neovascular Age-Related Macular Degeneration · 2019	Their institution	$36,779
Genentech, Inc. · Avenue · 2019	Their institution	$36,289
Aerie Pharmaceuticals, Inc. · A Multicenter, Open-Label, Safety and Proof-of-Concept Study To Assess Safety, Tolerability and Efficacy of Ar-1105 in Subjects With Macular Edema Due To Retinal Vein Occlusion (Rvo) · 2019	Their institution	$34,939
Aerie Pharmaceuticals, Inc. · A Study Assessing Ar-13503 Implant Alone and in Combination With Aflibercept in Subjects With Namd Or Dme · 2020	Their institution	$33,909
Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2020	Their institution	$28,093
Grifols, S.A. · A Double-Masked, Placebo-Controlled, Dose Ranging Study To Evaluate the Efficacy of Oral Akst4290 With Loading Doses of Aflibercept in Patients With Newly Diagnosed Neovascular Age-Related Macular Degeneration · 2021	Their institution	$27,016
Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2021	Their institution	$23,774
Aerie Pharmaceuticals, Inc. · A Study Assessing Ar-13503 Implant Alone and in Combination With Aflibercept in Subjects With Namd Or Dme · 2019	Their institution	$23,637
Boehringer Ingelheim Pharmaceuticals, Inc. · Anti Sema3a for Dmi in Treated Pdr Patients · 2022	Their institution	$22,856
Genentech, Inc. · Phase 2 of Ro7171009 in Ga · 2023	Their institution	$22,450
Boehringer Ingelheim Pharmaceuticals, Inc. · Anti Sema3a for Dmi in Treated Pdr Patients · 2021	Their institution	$20,045
EyePoint Pharmaceuticals US, Inc. · A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of Eyp-1901, A Tyrosine Kinase Inhibitor (Tki), Compared To Aflibercept in Subjects With Wet Amd · 2024	Their institution	$19,643
Hoffmann-La Roche Limited · A Phase I, Multi-Center, Multi-Part Study To Investigate Safety, Tolerability, Pk, Pd, and Immunogenicity of Ro7669330 Intravitreal Injections in Participants With Ga Secondary To Amd: Part 1a: Open-Label, Mad; Part 1b: Randomized Pd Pilot; Part 2: Masked, Randomized, Active-Comparator-Controlled · 2025	Their institution	$19,198
Boehringer Ingelheim Pharmaceuticals, Inc. · Anti Sema3a for Dmi in Treated Pdr Patients · 2023	Their institution	$17,508
Genentech, Inc. · Port Delivery System for Ranibizumab · 2019	Their institution	$17,262
Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2023	Their institution	$16,712
Apellis Pharmaceuticals, Inc. · Study To Evaluate the Safety of Intravitreal Apl-2 in Patients Diagnosed With Geographic Atrophy · 2022	Their institution	$16,437
Genentech, Inc. · Port Delivery System for Ranibizumab · 2021	Their institution	$16,287
Alcon Research LLC · A Study Assessing Ar-13503 Implant Alone and in Combination With Aflibercept in Subjects With Namd Or Dme · 2022	Their institution	$16,232
Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2024	Their institution	$15,615
TOPCON CORPORATION · Protocol Tpc2020-001 Oct Technology and Software Evaluation · 2020	Their institution	$15,500
Boehringer Ingelheim Pharmaceuticals, Inc. · Srd Mrd Pocm in Wamd · 2022	Their institution	$15,000
Alexion Pharmaceuticals, Inc. · A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (Alxn2040) in Patients With Geographic Atrophy (Ga) Secondary To Age Related Macular Degeneration (Amd) · 2024	Their institution	$14,899
Novartis Pharmaceuticals Corporation · A Randomized, Active-Controlled, Subject and Investigator-Masked, Multiple Dose Proof-of-Concept Study of Intravitreal Lka651 in Patients With Diabetic Macular Edema · 2024	Their institution	$14,008
Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Masked Phase 3a Study To Assess Safety and Efficacy of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks in Patients With Neovascular Age Related Macular Degeneration Namd With Persistent Retinal Fluid · 2022	Their institution	$12,690
Genentech, Inc. · Phase 2 of Ro7171009 in Ga · 2019	Their institution	$11,800
Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2023	Their institution	$11,710
Genentech, Inc. · Phase 2 of Ro7171009 in Ga · 2021	Their institution	$11,294
Genentech, Inc. · Port Delivery System of Ranizibumab Extension Study · 2021	Their institution	$10,795
Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2022	Their institution	$10,480
Genentech, Inc. · Iamd Observational Study · 2023	Their institution	$10,200
Boehringer Ingelheim International GmbH · Eye-Dmi Epidemiology Study · 2021	Their institution	$10,186
Genentech, Inc. · Anti Factor D in Ga Open Label Extension Study · 2019	Their institution	$9,655
Novo Nordisk AS · Ozempic · 2024	Their institution	$9,525
Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2023	Their institution	$9,453
Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2022	Their institution	$9,339
Novo Nordisk AS · 2021	Their institution	$8,675
Regeneron Pharmaceuticals, Inc. · Eylea Clinical Development Program · 2021	This clinician	$8,528
Boehringer Ingelheim Pharma GmbH & Co.KG · Phase I Srd · 2020	Their institution	$8,357
EyePoint Pharmaceuticals US, Inc. · A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of Eyp-1901, A Tyrosine Kinase Inhibitor (Tki), in Subjects With Wet Amd · 2021	Their institution	$8,000
Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2025	Their institution	$7,936
Genentech, Inc. · Phase 2 of Ro7171009 in Ga · 2022	Their institution	$6,725
Genentech, Inc. · Phase 2 of Ro7171009 in Ga · 2020	Their institution	$6,604
EyePoint Pharmaceuticals US, Inc. · A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of Eyp-1901, A Tyrosine Kinase Inhibitor (Tki), in Subjects With Wet Amd · 2022	Their institution	$6,140
Alexion Pharmaceuticals, Inc. · A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (Alxn2040) in Patients With Geographic Atrophy (Ga) Secondary To Age Related Macular Degeneration (Amd) · 2022	Their institution	$6,000
Boehringer Ingelheim Pharma GmbH & Co.KG · Phase I Srd and MD · 2021	Their institution	$5,384
Alexion Pharmaceuticals, Inc. · A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (Alxn2040) in Patients With Geographic Atrophy (Ga) Secondary To Age Related Macular Degeneration (Amd) · 2025	Their institution	$5,259
Novo Nordisk AS · Ozempic · 2022	Their institution	$4,650
Regeneron Pharmaceuticals, Inc. · Eylea Clinical Development Program · 2022	This clinician	$4,090
Boehringer Ingelheim International GmbH · Eye-Dmi Epidemiology Study · 2024	Their institution	$4,000
Boehringer Ingelheim Finland Ky · Anti-Sema3a for Dmi in Treated Pdr Patients · 2021	Their institution	$3,997
Boehringer Ingelheim Pharma GmbH & Co.KG · Phase I Srd · 2022	Their institution	$3,947
Novo Nordisk AS · Ozempic · 2023	Their institution	$3,875
Boehringer Ingelheim Pharma GmbH & Co.KG · Phase I Srd · 2021	Their institution	$3,597
Regeneron Pharmaceuticals, Inc. · A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe To Severe Nonproliferative Diabetic Retinopathy · 2020	This clinician	$3,405
Genentech, Inc. · A Multicenter Open Label Extension Study To Evaluate the Long Term Safety of Lampalizumab · 2019	Their institution	$2,000
Boehringer Ingelheim Pharma GmbH & Co.KG · Srd/Mrd/Pocm in Wamd · 2020	Their institution	$1,476
Regeneron Pharmaceuticals, Inc. · A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe To Severe Nonproliferative Diabetic Retinopathy · 2021	This clinician	$1,339
Novartis Pharmaceuticals Corporation · A Randomized, Active-Controlled, Subject and Investigator-Masked, Multiple Dose Proof-of-Concept Study of Intravitreal Lka651 in Patients With Diabetic Macular Edema · 2021	Their institution	$1,302
Boehringer Ingelheim Finland Ky · Anti-Sema3a for Dmi in Treated Pdr Patients · 2020	Their institution	$1,030
Boehringer Ingelheim Pharma GmbH & Co.KG · Phase I Srd · 2019	Their institution	$1,020
Novartis Pharmaceuticals Corporation · A Randomized, Active-Controlled, Subject and Investigator-Masked, Multiple Dose Proof-of-Concept Study of Intravitreal Lka651 in Patients With Diabetic Macular Edema · 2022	Their institution	$840
Novartis Pharmaceuticals Corporation · A Randomized, Active-Controlled, Subject and Investigator-Masked, Multiple Dose Proof-of-Concept Study of Intravitreal Lka651 in Patients With Diabetic Macular Edema · 2020	Their institution	$770
Novartis Pharmaceuticals Corporation · A Randomized, Active-Controlled, Subject and Investigator-Masked, Multiple Dose Proof-of-Concept Study of Intravitreal Lka651 in Patients With Diabetic Macular Edema · 2019	Their institution	$630
Regeneron Pharmaceuticals, Inc. · A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe To Severe Nonproliferative Diabetic Retinopathy · 2019	This clinician	$454
Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema · 2025	This clinician	$432
Boehringer Ingelheim Pharma GmbH & Co.KG · Srd/Mrd/Pocm in Wamd · 2021	Their institution	$213
Novartis Pharmaceuticals Corporation · A Two Year, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due To Diabetic Macular Edema · 2022	Their institution	$80
Novartis Pharmaceuticals Corporation · A Two Year, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due To Diabetic Macular Edema · 2023	Their institution	$1

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 100.0 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1295736916
Licence: CA G25107California G25107: Current · expires 2027-03-31
Group: Retina Vitreous Associates Medical Group
Gender: Male

More record details

Sole proprietor: No
Medicaid ID: CA 00G251070
Taxonomy: Federal specialty code 207W00000X (207W00000X)
Mailing address: 1245 Wilshire Blvd Ste 380, Los Angeles, CA, 90017
NPI first listed: 2005-08-03
NPI last updated: 2020-01-23
NPI record certified: 2020-01-23

This is when the NPI record was last certified, not a medical board exam.

Offices

Plan participation

California Medical Board record

School, training and certification

Specialty certification

Original Medicare doctor bills

Procedures year by year

Who their Medicare patients are

Year by year

2023: 21 services

2022: 22 services

2021: 21 services

2020: 23 services

2019: 31 services

2018: 25 services

2017: 29 services

2016: 34 services

2015: 29 services

2014: 30 services

2013: 35 services

Medicaid work

2023

2022

2021

2020

2019

2018

Drugs they prescribed that Part D paid

Year by year

2023: 27 drugs

2022: 26 drugs

2021: 28 drugs

2020: 31 drugs

2019: 30 drugs

2018: 34 drugs

2017: 27 drugs

2016: 28 drugs

2015: 29 drugs

2014: 28 drugs

2013: 32 drugs

Money from drug and device companies

Avirmax Biopharma, Inc

2024: $141,884

2023: $41,594

2022: $50,735

2021: $56,215

2020: $50,809

2019: $47,979

Research money

Checkups this office reported

Professional record